The Northwell Health Cancer Institute and its Center for Genomic Medicine opened Long Island’s first clinical Molecular Diagnostics Laboratory, a $3.2 million 2,800 square foot state-of-the-art facility with technology of next-generation sequencing that provides point-of-care tumor and patient genomic profiling to inform precision cancer therapy.
As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments. Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...
